[go: up one dir, main page]

KR900016211A - 신규 화합물 - Google Patents

신규 화합물 Download PDF

Info

Publication number
KR900016211A
KR900016211A KR1019900005136A KR900005136A KR900016211A KR 900016211 A KR900016211 A KR 900016211A KR 1019900005136 A KR1019900005136 A KR 1019900005136A KR 900005136 A KR900005136 A KR 900005136A KR 900016211 A KR900016211 A KR 900016211A
Authority
KR
South Korea
Prior art keywords
compound
group
general formula
compound according
chloro
Prior art date
Application number
KR1019900005136A
Other languages
English (en)
Other versions
KR0185378B1 (ko
Inventor
시드니 오어레크 배리
마아크 브로밋지 스티븐
댑스 스티븐
Original Assignee
원본미기재
비이참 그루우프 피이엘시이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898908365A external-priority patent/GB8908365D0/en
Priority claimed from GB898923299A external-priority patent/GB8923299D0/en
Application filed by 원본미기재, 비이참 그루우프 피이엘시이 filed Critical 원본미기재
Publication of KR900016211A publication Critical patent/KR900016211A/ko
Application granted granted Critical
Publication of KR0185378B1 publication Critical patent/KR0185378B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

내용 없음.

Description

신규 화합물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (14)

  1. 하기 일반식(I)의 화합물 또는 제약학적으로 허용가능한 그들의 염.
    상기식에서 R1은
    (여기서, 각 p와 q는 독립적으로 2-4의 정수를 나타내고, r은 2-4의 정수를 나타내고, S는 1 또는 2를 나타내고, t는 0 또는 1을 나타냄)을 나타내고; R2는 기 OR4(여기서, R4는 C1-4알킬, C2-4알케닐, C2-4알키닐임), 기 OCOR5(여기서, R5는 수소 또는 R1임) 또는 기 NHR6또는NR7R8(여기서, R6, R7및 R8은 독립적으로 C1-2알킬임)이고; R2는 클로로, 플루오로, 브로모, 시클로프로필, 1-3의 할로겐원자로 치환된 C1-3알킬 이거나, R3는 기(CH2)nR9기 (여기서, R9은 -CN, -OH, -OCH3, -SH, -SCH3, -C=CH 또는 -CH=CH2이고 n은 0 또는 1이며, 단 n이 0일때, R9는 -OH 또는 -SH가 아님)이다.
  2. 제1항에 있어서, p가 2를 나타내고, q는 2 또는 3을 나타내거나, 조합(r,s,t)가 값(2, 2, 0), (2, 1, 1), (3, 1, 1), (2, 1, 0) 또는 (3, 1, 0)을 취한 화합물.
  3. 제1항 또는 제2항에 있어서, R2가 메톡시, 에톡시, 아릴옥시, 프로파르길옥시, 아세톡시 또는 디메틸아미노인 화합물.
  4. 제1항 내지 제3항 중 어느 한 항에 있어서, R3가 시클로프로필, 클로로, 플루오로, 브로모, CN, OCH3, -C≡CH 또는 -CH2CN인 화합물.
  5. 또는 임의의 전술한 화합물의 제약학적으로 허용가능한 염.
  6. (a) 일반식(II) :
    (여기서, R1및 R3는 제1항에서 정의된 대로임)의 화합물을 일반식(III) :
    R´2-NH2(III)
    (여기서, R´2는 R2제1항에서 정의된 대로임) 또는 히드록시를 나타내고, R´3는 R3또는 그들로 전환가능한 기임)의 화합물과 반응시키고, R´2를 히드록시일때, R2로 전환시키고, R´3를 R3가 아닐때 R3로 전환시키고난후, 임의로 제약학적으로 허용가능한 염을 제조하거나: (b) 일반식(IV) :
    (여기서, R1는 R2(제1항에서 정의된 대로임)의 화합물을 R´3친핵제를 생성시킬 수 있는 일반식(V) :
    M-R´3(V)
    (여기서, R´3는 R3(제1항에서 정의된 대로임)또는 그들로 전환가능한 기임)의 화합물과 반응시키고 R´3를 R3가 아닐때, R3로 전환시키고 난후, 임의로 제약학적으로 허용가능한 염을 제조하거나: (c) 일반식(IVa) :
    (여기서, R1및 R2는 제1항에서 정의된 대로임)의 화합물을 염소화제, 브롬화제 또는 불소화제와 반응시키고, R3를 클로로 또는 브로모일때 임의로 다른 R3로 전환시키고 난후, 임의로 제약학적으로 허용가능한 염을 제조하는 것으로 구성된, 제1항의 화합물 또는 제약학적으로 허용가능한 그들의 염의 제조방법.
  7. 하기 일반식(IIb)의 화합물 또는 그들의 염 :
    상기식에서 R1및 R3는 제1항에서 정의된 대로이고, R3는 클로로 또는 브로모메틸이외의 것이다.
  8. 하기 일반식(IVa)의 화합물 :
    상기식에서, R1및 R2는 제1항에서 정의된 대로이다.
  9. 하기 일반식(IIb)의 화합물 :
    상기식에서, R´2는 R2또는 히드록시를 나타내고 R´3는 R3또는 그들로 전환가능한 기를 나타내고, R1, R2및 R3는 제1항에서 정의된 대로이며, 단 R´3가 R3일때, R´2는 R2가 아니다.
  11. 제1항에 따른 화합물 및 제약학적으로 허용가능한 담체로 구성된 제약학적 조성물.
  12. 활성 치료 물질로 사용하기 위한 제1항에 따른 화합물.
  13. 치매 치료 및/또는 예방에 사용하기위한 제1항에 따른 화합물.
  14. 치매 치료 및/또는 예방을 위한 의약 제조를 위한 제1항에 따른 화합물의 사용.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900005136A 1989-04-13 1990-04-13 신규 아자비시클릭 화합물, 그의 용도 및 제조방법 KR0185378B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB898908365A GB8908365D0 (en) 1989-04-13 1989-04-13 Novel compounds
GB89083653 1989-04-13
GB8908365.3 1989-10-16
GB898923299A GB8923299D0 (en) 1989-10-16 1989-10-16 Novel compounds
GB8923299.5 1989-10-16

Publications (2)

Publication Number Publication Date
KR900016211A true KR900016211A (ko) 1990-11-12
KR0185378B1 KR0185378B1 (ko) 1999-05-01

Family

ID=26295213

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900005136A KR0185378B1 (ko) 1989-04-13 1990-04-13 신규 아자비시클릭 화합물, 그의 용도 및 제조방법

Country Status (13)

Country Link
US (1) USRE35593E (ko)
EP (1) EP0392803B1 (ko)
JP (3) JP2665818B2 (ko)
KR (1) KR0185378B1 (ko)
AT (1) ATE269330T1 (ko)
CA (1) CA2014379C (ko)
DE (1) DE69034146T2 (ko)
DK (1) DK0392803T3 (ko)
ES (1) ES2219636T3 (ko)
HK (1) HK1012365A1 (ko)
NZ (1) NZ233290A (ko)
PT (1) PT93753B (ko)
SG (1) SG48315A1 (ko)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9100779A (es) * 1990-08-24 1992-04-01 Beecham Group Plc Compuestos azabiciclicos y procedimiento para su preparacion
GB9019095D0 (en) * 1990-09-01 1990-10-17 Beecham Group Plc Novel compounds
WO1992006959A1 (en) * 1990-10-12 1992-04-30 Beecham Group Plc 1,2,5,6-tetrahydropyridine oxime derivatives
WO1992011261A1 (en) * 1990-12-21 1992-07-09 Merck Sharp & Dohme Limited 4-azatricyclo[2.2.1.02,6]heptanes and pharmaceutical compositions
MX9300875A (es) * 1992-02-20 1993-08-31 Smithkline Beecham Plc Procedimiento para la preparacion de compuestos azabiciclicos.
GB9409718D0 (en) * 1994-05-14 1994-07-06 Smithkline Beecham Plc Novel compounds
GB9409705D0 (en) * 1994-05-14 1994-07-06 Smithkline Beecham Plc Novel compounds
GB9421472D0 (en) * 1994-10-25 1994-12-07 Smithkline Beecham Plc Novel methods
AR004178A1 (es) * 1995-07-29 1998-11-04 Smithkline Beecham Plc Procedimiento para la formulacion de un farmaco, una composicion farmaceutica obtenible mediante este procedimiento y el uso de la misma.
AU751607B2 (en) * 1995-07-29 2002-08-22 Smithkline Beecham Plc Method of treatment of dementia
CA2251851A1 (en) * 1996-05-13 1997-11-20 Roger Salmon Bicyclic amines as insecticides
GB9615628D0 (en) * 1996-07-25 1996-09-04 Smithkline Beecham Plc Formulation
US20010003588A1 (en) * 1996-09-12 2001-06-14 Smithkline Beecham Corporation Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2.]oct-3-yl)acetonitrile monohydrochloride
GB9619074D0 (en) * 1996-09-12 1996-10-23 Smithkline Beecham Plc Composition
WO1998046226A1 (en) * 1997-04-11 1998-10-22 Eli Lilly And Company Method for treating schizophrenia
GB9815383D0 (en) * 1998-07-15 1998-09-16 Smithkline Beecham Plc Novel method of treatment
KR20030021641A (ko) * 2001-09-07 2003-03-15 안병로 투명비누 자가제조용 키트 및 상기 키트를 이용한투명비누 자가제조방법
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
GB0607952D0 (en) * 2006-04-21 2006-05-31 Minster Res Ltd Novel treatment
GB0607946D0 (en) * 2006-04-21 2006-05-31 Minster Res The Ltd Mono and combination therapy
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2009002496A (es) 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
KR102287645B1 (ko) 2018-12-18 2021-08-06 한화솔루션 주식회사 실리카계 촉매를 이용한 배위-음이온 개환 중합에 의한 폴리아마이드의 제조방법 및 이에 의해 제조된 폴리아마이드

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ203861A (en) * 1982-04-14 1986-07-11 Beecham Group Plc Bicyclic heterocyclic compounds and pharmaceutical compositions containing such
FR2531955A1 (fr) * 1982-08-17 1984-02-24 Pharmuka Lab Nouveau procede de preparation de derives de la quinuclidine substitues en position 3
IL81610A (en) * 1986-02-27 1990-12-23 Roussel Uclaf Derivatives of 1,2,5,6-tetrahydropyridin-3-carboxaldehyde oxime,their preparation and pharmaceutical compositions containing them
DE3789039T2 (de) * 1986-06-27 1994-06-09 Beecham Group Plc Verbrückte bicyclische N-heterocyclische Verbindungen.
GB8615785D0 (en) * 1986-06-27 1986-08-06 Beecham Group Plc Compounds
US4786648A (en) * 1986-12-08 1988-11-22 Warner-Lambert Company O-substituted tetrahydropyridine oxime cholinergic agents
US4710508A (en) * 1986-12-08 1987-12-01 Warner-Lambert Company O-substituted tetrahydropyridine oxime cholinergic agents
US4798841A (en) * 1987-03-31 1989-01-17 Warner-Lambert Company Tetrahydropyridine oxime cholinergic agents and method of treatment
EP0287356B1 (en) * 1987-04-15 1996-01-24 Beecham Group Plc Bridgehead substituted azabicyclic derivatives
IT1203971B (it) * 1987-04-24 1989-02-23 Roussel Maestretti Spa Derivati di 1,2,5,6-tetraidropiridina, loro procedimento di preparazione e loro applicazione come medicamenti
IT1222529B (it) * 1987-08-21 1990-09-05 Roussel Maestretti Spa Derivati dell' ossima della 1,2,5,6-tetraidropirdin-3-carbossaldeide,loro procedimento di preparazione e loro impiego come sostanze medicinali
IT1222526B (it) * 1987-08-21 1990-09-05 Roussel Maestretti Spa Derivati dell' ossima della 1,2,5,6-tetraidropiridin-3-carbossaldeide,loro procedimento di preparazione e loro impiego come sostanze medicinali
IE63906B1 (en) * 1987-11-13 1995-06-14 Novo Nordisk As Azabicyclic compounds and their preparation and use
DE3738521C1 (de) * 1987-11-13 1988-12-01 Delta Getriebe Gmbh Planetengetriebe
IT1233446B (it) * 1987-12-30 1992-04-01 Roussel Maestretti Spa Derivati della 3 piperidinocarbaldeide ossima, loro procedimento di preparazione e loro applicazione come farmaci
US5110828A (en) * 1988-04-15 1992-05-05 Beecham Group P.L.C. Azabicyclo oxime derivatives
IT1227436B (it) * 1988-10-28 1991-04-11 Roussel Maestretti Spa Derivati di 1-azabicicloalcani, loro procedimento di preparazione e loro applicazione come farmaci
US4937239A (en) * 1989-02-13 1990-06-26 Warner-Lambert Company Azabicycloalkane oxime & azabicycloalkene oxime muscarinic agents
EP0402056A3 (en) * 1989-06-06 1991-09-04 Beecham Group p.l.c. Azabicyclic compounds, process for their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
DE69034146T2 (de) 2005-07-14
AU5315990A (en) 1990-10-18
JP2913467B2 (ja) 1999-06-28
ES2219636T3 (es) 2004-12-01
EP0392803A1 (en) 1990-10-17
NZ233290A (en) 1992-06-25
USRE35593E (en) 1997-08-19
KR0185378B1 (ko) 1999-05-01
EP0392803B1 (en) 2004-06-16
JPH09188679A (ja) 1997-07-22
PT93753B (pt) 1996-08-30
JPH09188678A (ja) 1997-07-22
CA2014379A1 (en) 1990-10-13
PT93753A (pt) 1990-11-20
SG48315A1 (en) 1998-04-17
JPH037285A (ja) 1991-01-14
CA2014379C (en) 2000-02-08
JP2665818B2 (ja) 1997-10-22
JP2913466B2 (ja) 1999-06-28
ATE269330T1 (de) 2004-07-15
HK1012365A1 (en) 1999-07-30
DK0392803T3 (da) 2004-10-18
DE69034146D1 (de) 2004-07-22
AU619969B2 (en) 1992-02-06

Similar Documents

Publication Publication Date Title
KR900016211A (ko) 신규 화합물
KR900700494A (ko) 마크로시클릭 화합물
IL59487A0 (en) Derivatives of 3-aminopropane-1,2-diol,their preparation and pharmaceutical compositions containing them
HUP0004040A1 (hu) Antimikrobiális hatású pleuromutilinszármazékok, eljárás ezek előállítására, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
ES2193142T3 (es) Uso de benzotiofenos para el tratamiento de hipercolesterolemia.
KR890005143A (ko) 17위치에서 3,4 또는 6개의 결합을 갖는 스피로 고리를 함유한 신규 스테로이드, 그의 제조 방법 및 제조용 중간체, 의약품으로서 그의 용도 및 이것을 함유하는 제약조성물.
FR2373513A1 (fr) Nouveaux derives du naphtalene, leur preparation et leur application comme medicaments
KR920003968A (ko) 염증성 장 질환의 치료방법
HU906284D0 (en) Process for the production of 24-homo-d-vitamin derivatives and medical preparations containing them as active agents
ATE73780T1 (de) Glutaminsaeure-derivate, verfahren und zwischenprodukte zu ihrer herstellung und diese enthaltende pharmazeutische formulierungen.
DK0474712T3 (da) Anvendelse af lysolecitinderivater til fremstilling af et farmaceutisk præparat
KR920021141A (ko) 갈륨 화합물
KR900016221A (ko) 6-아릴-치환된-4H-티에노[2,3-e][1,2,4]트리아졸로 [3,4-c][1,4] 디아제핀
KR910002437A (ko) 항염증성 조성물, 항알레르기성 조성물 또는 이들 혼합성질의 조성물
FR2366285A1 (fr) (3-amino-5-substitue-6-fluoropyrazinoyl ou pyrazamido) guanidines et leurs derives portant des substituants sur les atomes d'azote du noyau de guanidine, utiles comme medicaments
KR910014380A (ko) 이미자조피리다진 화합물, 그의 제법 및 용도
GB1309679A (en) Substituted sulphonanilides
KR890015995A (ko) 프로판아민 유도체
ATE5407T1 (de) 2-substituierte triazolo(4,3-a)pyridin-3(2h)-one, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen zur behandlung von depressionen.
FR2412555A1 (fr) Composes polyfluorohydroxyisopropyl carbostyriles tricycliques antihypertensifs, leur preparation et compositions pharmaceutiques les contenant
KR960705101A (ko) 비스스티릴 화합물을 기초로 하는 증백제 혼합물(brightening mixtures based on bistyryl compounds)
KR910002853A (ko) 도파민 효능제
KR930010004A (ko) 아미노알킬 치환 5,6-디히드로-디벤즈[b,e]아제핀-6,11-디온-11-옥심
IE800019L (en) N, n-disubstituted-aminomethyl-phenylethanylamines
KR930017906A (ko) 술포닐벤질 치환 이미다조피리딘

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19900413

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19950407

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19900413

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19980330

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19980922

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19981126

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19981224

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19981224

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20011029

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20021031

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20031106

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20041018

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20051014

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20061020

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20071011

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20081014

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20091016

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 20101129

Start annual number: 13

End annual number: 13

FPAY Annual fee payment

Payment date: 20111129

Year of fee payment: 14

PR1001 Payment of annual fee

Payment date: 20111129

Start annual number: 14

End annual number: 14

FPAY Annual fee payment

Payment date: 20121129

Year of fee payment: 15

PR1001 Payment of annual fee

Payment date: 20121129

Start annual number: 15

End annual number: 15

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20140624

Termination category: Expiration of duration